J&J grabs an option to buy a NASH drug in latest string of biotech deals
J&J has grabbed an option to buy Bird Rock Bio and its experimental NASH drug candidate, the CB1-targeting antibody namacizumab, if the pharma giant likes what it sees in an ongoing Phase I study.
La Jolla, CA-based Bird Rock, which changed its name from RuiYi, is going after the Cannabinoid receptor 1, which J&J also believes has potential for treating diabetic kidney disease. No terms were given for their option and collaboration, which topped J&J’s latest batch of deals from its global business development team.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.